187 related articles for article (PubMed ID: 32943881)
1. Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report.
He L; Zhang F; Ma Y; Zuo L; Xu Y
Onco Targets Ther; 2020; 13():8749-8756. PubMed ID: 32943881
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.
Gao Z; Xu J; Wang Y; Wu J; Sun T
Front Oncol; 2021; 11():715554. PubMed ID: 34722261
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
[TBL] [Abstract][Full Text] [Related]
5. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
Li Q; Wang Y; Zhu M; Gu Y; Tang Y
Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.
Liu M; Zhou X
Gland Surg; 2023 Feb; 12(2):317-323. PubMed ID: 36915810
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
[TBL] [Abstract][Full Text] [Related]
8. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.
Xu J; Chen J; Huang P; Zhou H; Wang X; Chen Z
Transl Breast Cancer Res; 2023; 4():25. PubMed ID: 38751473
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
11. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study.
Yao DS; Wang W; Chang JY; Zhang Y; Zhang HW; Xu JX; Cai HF
Gland Surg; 2021 Dec; 10(12):3362-3368. PubMed ID: 35070896
[TBL] [Abstract][Full Text] [Related]
13. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
Front Oncol; 2022; 12():855512. PubMed ID: 35463365
[TBL] [Abstract][Full Text] [Related]
14. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
Xie N; Liu L; Tian C; Hu Z; Ouyang Q
Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
[TBL] [Abstract][Full Text] [Related]
15. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
Li J; Shui Z; Ouyang Q
Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
[TBL] [Abstract][Full Text] [Related]
17. Inetetamab combined with pyrotinib and chemotherapy in the treatment of breast cancer brain metastasis: A case report.
Dou QQ; Sun TT; Wang GQ; Tong WB
World J Clin Cases; 2024 Jan; 12(3):575-581. PubMed ID: 38322469
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
19. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
Zhu W; Wu J; Cui M; Zhang L
Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
[TBL] [Abstract][Full Text] [Related]
20. Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients.
Chen Y; Zhang T; Zhang R; Cao X
Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38527247
[No Abstract] [Full Text] [Related]
[Next] [New Search]